resTORbio (NASDAQ:TORC) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of resTORbio (NASDAQ:TORC) from a hold rating to a sell rating in a research report released on Tuesday morning, Zacks.com reports.

According to Zacks, “resTORbio, Inc. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of therapeutics for the treatment of aging-related diseases. The company’s program consists of rapamycin complex 1 pathway to treat aging-related diseases and conditions. Its lead product candidate, RTB101 is an orally administered, small molecule, potent TORC1 inhibitor which is in clinical stage. resTORbio, Inc. is based in BOSTON, United States. “

Separately, Guggenheim started coverage on resTORbio in a report on Tuesday, June 4th. They set a buy rating and a $28.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $19.50.

Shares of NASDAQ:TORC opened at $10.00 on Tuesday. The stock has a market capitalization of $377.41 million, a P/E ratio of -7.04 and a beta of 3.26. resTORbio has a 1-year low of $6.21 and a 1-year high of $16.66. The business has a 50-day moving average price of $10.13 and a two-hundred day moving average price of $8.61.

resTORbio (NASDAQ:TORC) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.12). Sell-side analysts expect that resTORbio will post -2.1 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in TORC. Rhumbline Advisers bought a new stake in shares of resTORbio in the 1st quarter valued at about $69,000. Parametric Portfolio Associates LLC bought a new stake in shares of resTORbio in the 2nd quarter valued at about $146,000. Bank of New York Mellon Corp increased its stake in shares of resTORbio by 9.9% in the 4th quarter. Bank of New York Mellon Corp now owns 27,788 shares of the company’s stock valued at $239,000 after acquiring an additional 2,497 shares during the last quarter. Marshall Wace North America L.P. increased its stake in shares of resTORbio by 1,292.1% in the 1st quarter. Marshall Wace North America L.P. now owns 31,085 shares of the company’s stock valued at $212,000 after acquiring an additional 28,852 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of resTORbio by 6.5% in the 4th quarter. Bank of America Corp DE now owns 46,266 shares of the company’s stock valued at $398,000 after acquiring an additional 2,809 shares during the last quarter. 52.11% of the stock is owned by hedge funds and other institutional investors.

resTORbio Company Profile

resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.

Featured Article: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on resTORbio (TORC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.